000			02324 a2200697 4500
005			20250517045220.0
264		0	_c20170309
008			201703s 0 0 eng d
022			_a1473-1150
024	7		_a10.1038/tpj.2015.54 _2doi
040			_aNLM _beng _cNLM
100	1		_aKjersem, J B
245	0	0	_aAGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. _h[electronic resource]
260			_bThe pharmacogenomics journal _c06 2016
300			_a272-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBiomarkers, Tumor _xgenetics
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aColorectal Neoplasms _xdrug therapy
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aFluorouracil _xadverse effects
650	0	4	_aGenetic Association Studies
650	0	4	_aGenotype
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultidrug Resistance-Associated Protein 2
650	0	4	_aNeoplasm Metastasis
650	0	4	_aOrganoplatinum Compounds _xadverse effects
650	0	4	_aOxaliplatin
650	0	4	_aPharmacogenomic Variants _xgenetics
650	0	4	_aPhenotype
650	0	4	_aPolymorphism, Single Nucleotide
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRetrospective Studies
650	0	4	_aRisk Factors
650	0	4	_aScandinavian and Nordic Countries
650	0	4	_aTime Factors
650	0	4	_aTransaminases _xgenetics
650	0	4	_aTreatment Outcome
650	0	4	_aXeroderma Pigmentosum Group D Protein _xgenetics
650	0	4	_aYoung Adult
700	1		_aThomsen, M
700	1		_aGuren, T
700	1		_aHamfjord, J
700	1		_aCarlsson, G
700	1		_aGustavsson, B
700	1		_aIkdahl, T
700	1		_aIndrebø, G
700	1		_aPfeiffer, P
700	1		_aLingjærde, O
700	1		_aTveit, K M
700	1		_aWettergren, Y
700	1		_aKure, E H
773	0		_tThe pharmacogenomics journal _gvol. 16 _gno. 3 _gp. 272-9
856	4	0	_uhttps://doi.org/10.1038/tpj.2015.54 _zAvailable from publisher's website
999			_c25157415 _d25157415